Error bars show 95% confidence intervals. Studies are arranged in order of decreasing magnitude of risk estimate, except if a single study disaggregated progestin-only pills and combined oral contraceptives, in which case both estimates are adjacent (as indicated by a box around the study identifiers). Graph does not display estimates from marginal structural models (MSM). adjIRR, adjusted incidence risk ratio. adjHR, adjusted hazard ratio. COC, combined oral contraceptive. POP, progestin-only pills. OCs, oral contraceptives. *Analysis showed significant findings at P=0.05. ^ Unpublished estimates from a sub-analysis of Morrison 2015 meta-analysis, restricted to pooled analysis using databases not previously used to publish estimates on hormonal contraceptive methods and HIV acquisition risk. c. Good adherence to allocated treatments, with limited discontinuation or change of method of contraception. If occurs in less than 20% of trial participants (and most other criteria are met) may still be deemed 'informative but with few limitations'; if more than 20% affected but investigators adjusted appropriately for this in analysis may be 'informative with important limitations'; if more than 20% affected and no appropriate adjustment made, trial will be deemed 'unlikely to inform the primary question'.
d. Blinding of participants and study personnel to allocated treatments. e. Independently ascertained outcomes, with personnel responsible for ascertaining the main trial outcomes blind to allocated treatments.
f. High rates (> 80%) of follow up of trial participants resulting in high rates of ascertainment of outcomes.
g. Analyses conducted blind to treatment allocation, with time varying analysis of key confounders, including estimates of condom use during the study; with intention to treat analyses the primary comparison between groups.
h. Results reported as per pre-defined analysis plan, with subgroup analyses predefined or clearly designated as post hoc analyses (and with a clear justification for their conduct).
It was recognised that many pragmatic trials in reproductive health care will not fulfill all of these criteria (for example, trials of different contraceptive methods are likely to be open, with participants and clinicians responsible for their routine care unblinded to the treatments allocated). Nonetheless, clarity about how the researchers sought to minimise bias and confounding after treatment allocation should enable a judgement to be made about the extent to which evidence from the trial was limited.
It is possible, although probably highly unlikely, that an observational study purposively established to investigate the possible association between hormonal contraception and HIV acquisition among users meets most of the above criteria. In such a situation a judgement will be made on whether that study was "informative with few limitations". 
